Logo image of SCYX

SCYNEXIS INC (SCYX) Stock Fundamental Analysis

USA - NASDAQ:SCYX - US8112922005 - Common Stock

0.69 USD
+0.1 (+16.95%)
Last: 11/20/2025, 8:25:43 PM
0.7099 USD
+0.02 (+2.88%)
Pre-Market: 11/21/2025, 8:15:51 AM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SCYX. SCYX was compared to 192 industry peers in the Pharmaceuticals industry. While SCYX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, SCYX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SCYX has reported negative net income.
SCYX had a negative operating cash flow in the past year.
In the past 5 years SCYX reported 4 times negative net income.
SCYX had negative operating cash flow in 4 of the past 5 years.
SCYX Yearly Net Income VS EBIT VS OCF VS FCFSCYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

SCYX has a Return On Assets (-32.16%) which is comparable to the rest of the industry.
SCYX has a Return On Equity of -43.89%. This is comparable to the rest of the industry: SCYX outperforms 55.73% of its industry peers.
Industry RankSector Rank
ROA -32.16%
ROE -43.89%
ROIC N/A
ROA(3y)-14.27%
ROA(5y)-24.82%
ROE(3y)-636.53%
ROE(5y)-446.25%
ROIC(3y)N/A
ROIC(5y)N/A
SCYX Yearly ROA, ROE, ROICSCYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

The Gross Margin of SCYX (114.98%) is better than 98.96% of its industry peers.
SCYX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for SCYX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 114.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.8%
GM growth 5YN/A
SCYX Yearly Profit, Operating, Gross MarginsSCYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

6

2. Health

2.1 Basic Checks

SCYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SCYX has been increased compared to 1 year ago.
The number of shares outstanding for SCYX has been increased compared to 5 years ago.
The debt/assets ratio for SCYX is higher compared to a year ago.
SCYX Yearly Shares OutstandingSCYX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SCYX Yearly Total Debt VS Total AssetsSCYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -8.93, we must say that SCYX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.93, SCYX is doing worse than 66.67% of the companies in the same industry.
There is no outstanding debt for SCYX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.93
ROIC/WACCN/A
WACC8.82%
SCYX Yearly LT Debt VS Equity VS FCFSCYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 5.20 indicates that SCYX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.20, SCYX is in the better half of the industry, outperforming 67.71% of the companies in the same industry.
SCYX has a Quick Ratio of 5.20. This indicates that SCYX is financially healthy and has no problem in meeting its short term obligations.
SCYX has a Quick ratio of 5.20. This is in the better half of the industry: SCYX outperforms 68.75% of its industry peers.
Industry RankSector Rank
Current Ratio 5.2
Quick Ratio 5.2
SCYX Yearly Current Assets VS Current LiabilitesSCYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

SCYX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.08%, which is quite impressive.
The Revenue for SCYX has decreased by -97.33% in the past year. This is quite bad
The Revenue has been growing by 99.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)31.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.33%
Revenue 1Y (TTM)-97.33%
Revenue growth 3Y-34.22%
Revenue growth 5Y99.01%
Sales Q2Q%-49.39%

3.2 Future

Based on estimates for the next years, SCYX will show a small growth in Earnings Per Share. The EPS will grow by 2.97% on average per year.
SCYX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.60% yearly.
EPS Next Y8.43%
EPS Next 2Y36.7%
EPS Next 3Y-0.41%
EPS Next 5Y2.97%
Revenue Next Year32.74%
Revenue Next 2Y72.19%
Revenue Next 3Y-39.59%
Revenue Next 5Y1.6%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SCYX Yearly Revenue VS EstimatesSCYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
SCYX Yearly EPS VS EstimatesSCYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SCYX. In the last year negative earnings were reported.
Also next year SCYX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCYX Price Earnings VS Forward Price EarningsSCYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCYX Per share dataSCYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.7%
EPS Next 3Y-0.41%

More info and screens

0

5. Dividend

5.1 Amount

SCYX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCYNEXIS INC

NASDAQ:SCYX (11/20/2025, 8:25:43 PM)

Premarket: 0.7099 +0.02 (+2.88%)

0.69

+0.1 (+16.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-10 2026-03-10/amc
Inst Owners26.58%
Inst Owner Change5.88%
Ins Owners2.09%
Ins Owner Change6.06%
Market Cap28.92M
Revenue(TTM)3.75M
Net Income(TTM)-19.52M
Analysts84.44
Price Target3.74 (442.03%)
Short Float %2.6%
Short Ratio1.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.07%
Min EPS beat(2)27.76%
Max EPS beat(2)38.38%
EPS beat(4)4
Avg EPS beat(4)36.63%
Min EPS beat(4)20.51%
Max EPS beat(4)59.89%
EPS beat(8)6
Avg EPS beat(8)23.48%
EPS beat(12)8
Avg EPS beat(12)7.4%
EPS beat(16)11
Avg EPS beat(16)17.41%
Revenue beat(2)2
Avg Revenue beat(2)395.48%
Min Revenue beat(2)22.61%
Max Revenue beat(2)768.35%
Revenue beat(4)2
Avg Revenue beat(4)152.71%
Min Revenue beat(4)-90.6%
Max Revenue beat(4)768.35%
Revenue beat(8)5
Avg Revenue beat(8)170.56%
Revenue beat(12)8
Avg Revenue beat(12)116.76%
Revenue beat(16)9
Avg Revenue beat(16)82.59%
PT rev (1m)-21.43%
PT rev (3m)-21.43%
EPS NQ rev (1m)7.69%
EPS NQ rev (3m)-33.33%
EPS NY rev (1m)39.23%
EPS NY rev (3m)-49.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-94.44%
Revenue NY rev (1m)289.57%
Revenue NY rev (3m)-8.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.88
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB 0.65
EV/EBITDA N/A
EPS(TTM)-0.51
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0.08
BVpS1.06
TBVpS1.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.16%
ROE -43.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 114.98%
FCFM N/A
ROA(3y)-14.27%
ROA(5y)-24.82%
ROE(3y)-636.53%
ROE(5y)-446.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.8%
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.2
Quick Ratio 5.2
Altman-Z -8.93
F-Score4
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.33%
EPS Next Y8.43%
EPS Next 2Y36.7%
EPS Next 3Y-0.41%
EPS Next 5Y2.97%
Revenue 1Y (TTM)-97.33%
Revenue growth 3Y-34.22%
Revenue growth 5Y99.01%
Sales Q2Q%-49.39%
Revenue Next Year32.74%
Revenue Next 2Y72.19%
Revenue Next 3Y-39.59%
Revenue Next 5Y1.6%
EBIT growth 1Y29.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-336.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-336.99%
OCF growth 3YN/A
OCF growth 5YN/A

SCYNEXIS INC / SCYX FAQ

Can you provide the ChartMill fundamental rating for SCYNEXIS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SCYX.


What is the valuation status of SCYNEXIS INC (SCYX) stock?

ChartMill assigns a valuation rating of 0 / 10 to SCYNEXIS INC (SCYX). This can be considered as Overvalued.


What is the profitability of SCYX stock?

SCYNEXIS INC (SCYX) has a profitability rating of 2 / 10.


What is the financial health of SCYNEXIS INC (SCYX) stock?

The financial health rating of SCYNEXIS INC (SCYX) is 6 / 10.